Alnylam Pharmaceuticals Inc (ALNY)
144.51
+0.80
(+0.56%)
USD |
NASDAQ |
Apr 26, 14:25
Alnylam Pharmaceuticals Enterprise Value: 16.68B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 16.68B |
| April 24, 2024 | 16.69B |
| April 23, 2024 | 16.98B |
| April 22, 2024 | 16.94B |
| April 19, 2024 | 16.77B |
| April 18, 2024 | 16.86B |
| April 17, 2024 | 16.88B |
| April 16, 2024 | 17.06B |
| April 15, 2024 | 17.18B |
| April 12, 2024 | 17.28B |
| April 11, 2024 | 17.74B |
| April 10, 2024 | 17.78B |
| April 09, 2024 | 18.22B |
| April 08, 2024 | 18.23B |
| April 05, 2024 | 17.92B |
| April 04, 2024 | 17.66B |
| April 03, 2024 | 17.58B |
| April 02, 2024 | 17.60B |
| April 01, 2024 | 17.89B |
| March 28, 2024 | 17.40B |
| March 27, 2024 | 18.03B |
| March 26, 2024 | 17.72B |
| March 25, 2024 | 17.73B |
| March 22, 2024 | 17.03B |
| March 21, 2024 | 17.05B |
| Date | Value |
|---|---|
| March 20, 2024 | 17.22B |
| March 19, 2024 | 17.24B |
| March 18, 2024 | 17.15B |
| March 15, 2024 | 17.38B |
| March 14, 2024 | 17.29B |
| March 13, 2024 | 17.27B |
| March 12, 2024 | 17.05B |
| March 11, 2024 | 17.36B |
| March 08, 2024 | 17.45B |
| March 07, 2024 | 17.46B |
| March 06, 2024 | 17.43B |
| March 05, 2024 | 17.43B |
| March 04, 2024 | 17.48B |
| March 01, 2024 | 17.80B |
| February 29, 2024 | 17.61B |
| February 28, 2024 | 18.13B |
| February 27, 2024 | 18.61B |
| February 26, 2024 | 18.56B |
| February 23, 2024 | 18.44B |
| February 22, 2024 | 19.09B |
| February 21, 2024 | 18.07B |
| February 20, 2024 | 17.43B |
| February 16, 2024 | 17.10B |
| February 15, 2024 | 17.15B |
| February 14, 2024 | 19.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.802B
Minimum
May 20 2019
28.44B
Maximum
Dec 21 2022
17.09B
Average
17.03B
Median
Mar 22 2024
Enterprise Value Benchmarks
| Ionis Pharmaceuticals Inc | 5.050B |
| Pfizer Inc | 201.07B |
| Blueprint Medicines Corp | 5.084B |
| Madrigal Pharmaceuticals Inc | 3.349B |
| Sarepta Therapeutics Inc | 11.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -137.87M |
| Revenue (Quarterly) | 439.72M |
| Total Expenses (Quarterly) | 556.12M |
| EPS Diluted (Quarterly) | -1.10 |
| Gross Profit Margin (Quarterly) | 80.47% |
| Profit Margin (Quarterly) | -31.35% |
| Earnings Yield | -2.46% |
| Normalized Earnings Yield | -2.080 |